TRAIL, Fas Ligand, TNF and TLR3 in Cancer

  • Olivier Micheau

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 12)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Jessica Wagner, Christina Leah Kline, Wafik El-Deiry
    Pages 1-25
  3. Lubna Danish, Daniela Stöhr, Peter Scheurich, Nadine Pollak
    Pages 27-57
  4. Laurence Dubrez, Simone Fulda
    Pages 59-77
  5. James Sledziona, Vivek M. Rangnekar
    Pages 91-106
  6. Amanda Poissonnier, Patrick Legembre
    Pages 131-157
  7. Yann Estornes, Toufic Renno, Serge Lebecque
    Pages 159-185
  8. Faustino Mollinedo, Consuelo Gajate
    Pages 187-227
  9. Fatima Bilal, Michaël Pérès, Nathalie Andrieu-Abadie, Thierry Levade, Bassam Badran, Ahmad Daher et al.
    Pages 229-245
  10. François Bertaux, Dirk Drasdo, Grégory Batt
    Pages 291-307
  11. Back Matter
    Pages 309-317

About this book


This volume provides the current understanding of death receptor's/TLR3 signaling regulation in cancer. Death receptors, including TRAIL-R1, TRAIL-R2, Fas and TNF-RI, owing to their ability to trigger apoptosis and to contribute to the elimination of cancer cells by the immune system have been considered, to variable extent, as important therapeutic targets for cancer therapy. But an increasing body of evidence suggests that some of these receptors may also contribute to tumorigenesis, or that new players such as TLR3 may be targeted for cancer therapy due to their ability to behave like death receptors.



Editors and affiliations

  • Olivier Micheau
    • 1
  1. 1.INSERM, LNC UMR 1231DijonFrance

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing AG 2017
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-56804-1
  • Online ISBN 978-3-319-56805-8
  • Series Print ISSN 2196-5501
  • Series Online ISSN 2196-551X
  • Buy this book on publisher's site